Two-year results after convective radiofrequency water vapor
thermal therapy of symptomatic benign prostatic hyperplasia

J 2016

Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia

DIXON, Christopher M., Edwin Rijo CEDANO, Dalibor PACÍK, Vítězslav VÍT, Gabriel VARGA et. al.

Základní údaje

Originální název

Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia

Autoři

DIXON, Christopher M. (840 Spojené státy), Edwin Rijo CEDANO (214 Dominikánská republika), Dalibor PACÍK (203 Česká republika, garant, domácí), Vítězslav VÍT (203 Česká republika, domácí), Gabriel VARGA (703 Slovensko, domácí), Lennart WAGRELL (752 Švédsko), Thayne R. LARSON (840 Spojené státy) a Lance A. MYNDERSE (840 Spojené státy)

Vydání

Research and Reports in Urology, Albany, Dove Medical Press Limited, 2016, 2253-2447

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Nový Zéland

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/16:00092313

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.2147/RRU.S119596

UT WoS

000390140300001

Klíčová slova anglicky

benign prostatic hyperplasia; lower urinary tract symptoms; convective RF; water vapor thermal therapy; minimally invasive

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 14. 1. 2017 22:18, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Objective: The objective of this study was to assess the effectiveness and safety of convective radiofrequency (RF) water vapor thermal therapy in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH); a pilot study design with 2-year follow-up evaluations. Patients and methods: Men aged >=45 years with an International Prostate Symptom Score >=13, a maximum urinary flow rate (Qmax) <=15 mL/s, and prostate volume 20–120 cc were enrolled in a prospective, open-label pilot study using convective RF water vapor energy with the Rezum System. Patients were followed up for 2 years after transurethral thermal treatment at 3 international centers in the Dominican Republic, Czech Republic, and Sweden. The transurethral thermal therapy utilizes radiofrequency to generate wet thermal energy in the form of water vapor injected through a rigid endoscope into the lateral lobes and median lobe as needed. Urinary symptom relief, urinary flow, quality of life (QOL) impact, sexual function, and adverseevents (AEs) were assessed at 1 week, 1, 3, 6, 12, and 24 months. Results: LUTS, flow rate, and QOL showed significant improvements from baseline; prostate volumes were appreciably reduced. Sexual function was maintained and no de novo erectile dysfunction occurred. The responses evident as early as 1 month after treatment remained consistent and durable over the 24 months of study. Early AEs were typically transient and mild to moderate; most were related to endoscopic instrumentation. No procedure related to late AEs were seen. Conclusion: The Rezum System convective RF thermal therapy is a minimally invasive treatment for BPH/LUTS which can be performed in the office or as an outpatient procedure with minimal associated perioperative AEs. It has no discernable effect on sexual function and provides significant improvement of LUTS that remain durable at 2 years.

Citovat

DIXON, Christopher M., Edwin Rijo CEDANO, Dalibor PACÍK, Vítězslav VÍT, Gabriel VARGA, Lennart WAGRELL, Thayne R. LARSON a Lance A. MYNDERSE. Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Research and Reports in Urology. Albany: Dove Medical Press Limited, 2016, roč. 8, "neuvedeno", s. 207-216. ISSN 2253-2447. Dostupné z: https://dx.doi.org/10.2147/RRU.S119596.

@article{1364891,
   author = {Dixon, Christopher M. and Cedano, Edwin Rijo and Pacík, Dalibor and Vít, Vítězslav and Varga, Gabriel and Wagrell, Lennart and Larson, Thayne R. and Mynderse, Lance A.},
   article_location = {Albany},
   article_number = {"neuvedeno"},
   doi = {http://dx.doi.org/10.2147/RRU.S119596},
   keywords = {benign prostatic hyperplasia; lower urinary tract symptoms; convective RF; water vapor thermal therapy; minimally invasive},
   language = {eng},
   issn = {2253-2447},
   journal = {Research and Reports in Urology},
   title = {Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia},
   volume = {8},
   year = {2016}
}

TY  - JOUR
ID  - 1364891
AU  - Dixon, Christopher M. - Cedano, Edwin Rijo - Pacík, Dalibor - Vít, Vítězslav - Varga, Gabriel - Wagrell, Lennart - Larson, Thayne R. - Mynderse, Lance A.
PY  - 2016
TI  - Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia
JF  - Research and Reports in Urology
VL  - 8
IS  - "neuvedeno"
SP  - 207-216
EP  - 207-216
PB  - Dove Medical Press Limited
SN  - 22532447
KW  - benign prostatic hyperplasia
KW  - lower urinary tract symptoms
KW  - convective RF
KW  - water vapor thermal therapy
KW  - minimally invasive
N2  - Objective: The objective of this study was to assess the effectiveness and safety of convective radiofrequency (RF) water vapor thermal therapy in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH); a pilot study design with 2-year follow-up evaluations. Patients and methods: Men aged >=45 years with an International Prostate Symptom Score >=13, a maximum urinary flow rate (Qmax) <=15 mL/s, and prostate volume 20–120 cc were enrolled in a prospective, open-label pilot study using convective RF water vapor energy with the Rezum System. Patients were followed up for 2 years after transurethral thermal treatment at 3 international centers in the Dominican Republic, Czech Republic, and Sweden. The transurethral thermal therapy utilizes radiofrequency to generate wet thermal energy in the form of water vapor injected through a rigid endoscope into the lateral lobes and median lobe as needed. Urinary symptom relief, urinary flow, quality of life (QOL) impact, sexual function, and adverseevents (AEs) were assessed at 1 week, 1, 3, 6, 12, and 24 months. Results: LUTS, flow rate, and QOL showed significant improvements from baseline; prostate volumes were appreciably reduced. Sexual function was maintained and no de novo erectile dysfunction occurred. The responses evident as early as 1 month after treatment remained consistent and durable over the 24 months of study. Early AEs were typically transient and mild to moderate; most were related to endoscopic instrumentation. No procedure related to late AEs were seen. Conclusion: The Rezum System convective RF thermal therapy is a minimally invasive treatment for BPH/LUTS which can be performed in the office or as an outpatient procedure with minimal associated perioperative AEs. It has no discernable effect on sexual function and provides significant improvement of LUTS that remain durable at 2 years.
ER  -

DIXON, Christopher M., Edwin Rijo CEDANO, Dalibor PACÍK, Vítězslav VÍT, Gabriel VARGA, Lennart WAGRELL, Thayne R. LARSON a Lance A. MYNDERSE. Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. \textit{Research and Reports in Urology}. Albany: Dove Medical Press Limited, 2016, roč.~8, ''neuvedeno'', s.~207-216. ISSN~2253-2447. Dostupné z: https://dx.doi.org/10.2147/RRU.S119596.

Podrobný výpis o publikaci